Translate page

List of interesting CML Publications 

Please click here to find a selection of other recent clinical and scientific CML publications from peer-reviewed journals. 


CML Publications 2016

Clinical Publications Scientific Publications
March 2016

Splenic irradication before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
(Gratwohl A et al. Ann Hematol, March 2016)
(epub ahead of print)

Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance
(Patkar N et al. Leuk Lymphoma, March 2016
(epub ahead of print) 
Rotation of nilotinib and imatinib for first-line treatment of chronic myeloid leukemia
(Gugliotta G. Am J Hematol, March 2016
(epub ahead of print
Micro RNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia
Chakraborty C. et al. Oncotarget, March 2016) 
(epub ahead of print)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States
(Padula WV et al. J Natl Cancer Inst., March 2016
(epub ahead of print

Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3
(Wang H et al. Oncotarget, March 2016
(epub ahead of print)

New methodologies in the molecular monitoring of CML
(Yeung CC et al. Curr Hematol Malig Rep, March 2016
(epub ahead of print)

NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells
(Garcia-Alegría E et al. Cancer Lett, March 2016
(epub ahead of print)

Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and/or renal dysfunction
(Sasaki K et al. Clin Lymphoma Myeloma Leuk, March 2016)
c-MYB is a transcriptional regulator of ESPL1/separase in BCR-ABL-positive chronic myeloid leukemia
(Prinzhorn W et al. Biomark Res, March 2016) 
(epub ahead of print
Present and future of molecular monitoring in chronic myloid leukaemia
(Soverini S et al. Br J Haematol, March 2016) 
(epub ahead of print)
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients
(Alikian M et al. J Mol Diagn, March 2016)
Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era?
(Bansal A et al. Curr Opin Hematol, March 2016
(epub ahead of print)
February 2016
Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study
(Cortes JE et al. Clin Lymphoma Myeloma Leuk, February 2016) 
(epub ahead of print) 
High CIP2A levels correlates with an antiapoptoic phenotype that can be overcome by targeting BCL-XL in chronic meyloid leukemia
(Lucas CM et al. Leukemia, February 2016
(epub ahead of print)
Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia
(Caldemeyer L et al. Curr Hematol Malig Rep, February 2016) 
(epub ahead of print)

Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib resistance preventing rpS6 phosphorylation in chronic meyloid leukaemia cells: new combined therapeutic strategies
(Salizzato V et al. Oncotarget, February 2016
(epub ahead of print)

Hematologic malignancies in pregnancy: Management guidelines from an international consensus
Lishner M et al. J Clin Oncol, February 2016
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukemia
(Latham S et al. J Clin Pathol, February 2016
(epub ahead of print) 

Quality of life and long-term therapy in patients with chronic myeloid leukemia
(Flynn KE et al. Curr Hematol Malig Rep, 
February 2016
(epub ahead of print

Hsp90 inhibitor, BIIBo21, induces apoptosis and authopagy by regulating mTOR-UIIK1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemic cells
(He W et al. Int J Oncol, February 2016) 

Omacetaxine Mepesuccinate for chronic myeloid leukemia
(Rosshandler Y et al. Expert Rev Hematol, February 2016) 

Normal ABL1 is a tumour suppressor and therapeutic target in human and mouse leukemias expressing oncogeneic ABL1 kinase
(Dasgupta Y et al. Blood, February 2016
Analysis of 2013 European LeukemiaNET (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcome
Jain P et al. Br. J Hematol, February 2016)
Heterogeneity of leukemia-initiating capacity of chronic meylogenous leukemic stem cells
(Zhang B et al. J Clin Invest, February 2016)
(epub ahead of print)
Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring
(Jabbour E et al. Am J Hematol, February 2016)
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
(Deiniger MW et al. Blood, February 2015)
Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response and overall survival: A systemic review and meta-analysis
(Douxfils J et al. JAMA Oncol, February 2016)
(epub ahead of print)
The role of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review
(Di Stefano C et al. Oncol Rep, February 2016)
The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients
(Kurtovic-Kozaric A et al. Br J Haematol, 
February 2016

(epub ahead of print
Allogeneic transplantation for CML in the TKI era: striking the right balance
(Innes AJ et al. Nat Rev Clin Oncol, 
January 2016
Conditional survival with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
(Sasaki K et al. Cancer, January 2016)
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
(Parker WT et al. Blood, January 2016) 
(epub ahead of print)
Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France intergroup des leucémies myéloides chroniques
(Rea D et al. Bull Cancer, January 2016)
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia
(Tanrikulu Simsek E et al. J Clin Pathol, January 2016)
Dasatinib first-line: Multicentric Italian experience outside clinical trials
(Breccia M et al. Leuk Res, January 2016)

Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
(Jain P et al. Blood, January 2016

(epub ahead of print)

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
(Pfirrmann M et al. Leukemia, January 2016)

Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis

(Maxson JE et al. Cancer Res, January 2016)

Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase myeloid leukaemia resistant or intolerant to imatinib
Brümmendorf TH et al. Br J Haematol, 
January 2016
(epub ahead of print 
In silico identifcation of inhibitors against mutated BCR-ABL protein screening and molecular dynamics simultation study
(Kumar H et al. J Biomol Struct Dyn, January 2016)
(epub ahead of print) 
Conditioned survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
(Sasaki K et al. Cancer, January 2015 
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase
(Akard LP et al. Leuk Lymphoma, January 2016)
(epub ahead of print)

CML Publications 2014/2015

Access 2015 CML publications here
Access 2014 CML publications here


Search for more publications on CML at